GSK Pharma skids after Q4 PAT tumbles 90% YoY to Rs 14 cr

Glaxosmithkline Pharmaceuticals fell 1.75% to Rs 1,489.15 after the company's consolidated net profit tanked 89.6% to Rs 14.33 crore on 4.9% increase in net sales to Rs 813.75 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax (PBT) dropped 64.3% to Rs 63.01 crore in Q4 FY21 from Rs 176.55 crore in Q4 FY20. The Q4 result was declared post market hours yesterday, 18 May 2021.
On a standalone basis, revenue for the quarter came in at Rs 807 crore, recording an underlying growth of 6%. Total income came in at Rs 837 crore as compared to Rs 791 crore for the quarter ended 31st March 2020. PBT (before exceptional) for the quarter at Rs 180 crore, recorded a growth of 9%.

Related Keywords

Sridhar Venkatesh ,Glaxosmithkline ,Glaxosmithkline Pharmaceuticals ,Fluarix Tetra ,Direct Relief ,Capital Market ,Healthcare In India ,Pharmaceutical Industry In India ,India ,Harmaceuticals Nec ,Gsk Pharma ,Harmaceutical ,Healthcare ,Anti Infectives ,Cenveo ,Glaxosmithkline Plc ,Managing Director ,ஸ்ரீதர் வெங்கடேஷ் ,கிளாக்சோஸ்மித்க்லைன் ,கிளாக்சோஸ்மித்க்லைன் மருந்துகள் ,நேரடி துயர் நீக்கம் ,மூலதனம் சந்தை ,சுகாதாரம் இல் இந்தியா ,ந்திய ,